Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14186MR)

This product GTTS-WQ14186MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ANGPT2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001118887.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285
UniProt ID O15123
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ14186MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6755MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ1773MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ7065MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ13287MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ11270MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ8385MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ11319MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-524
GTTS-WQ3942MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-145
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW